The authors of this review and meta-analysis of phase III trials evaluated the use of daratumumab for the treatment of newly diagnosed and relapsed/refractory multiple myeloma. While the individual trials did not demonstrate a statistically significant survival benefit, the meta-analysis did showed improvement in both progression-free and overall survival with daratumumab for both standard-risk and high-risk multiple myeloma.
These results support the addition of daratumumab to standard backbone myeloma therapies in both standard- and high-risk settings for newly diagnosed and relapsed/refractory patients.
